

## Monthly statement of total voting rights and shares forming the company's share capital

Article L233-8-II of the French Commercial Code  
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris, Compartment C  
ISIN code: FR0012616852

| Date         | Number of shares outstanding | Total voting rights        |                          |
|--------------|------------------------------|----------------------------|--------------------------|
|              |                              | Total gross <sup>(1)</sup> | Total net <sup>(2)</sup> |
| May 31, 2018 | 18,308,263                   | 18,308,263                 | 18,241,085               |

- <sup>(1)</sup> The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- <sup>(2)</sup> The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

### About Cerenis Therapeutics: [www.cerenis.com](http://www.cerenis.com)

CERENIS Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids is removed from arteries and is transported to the liver for elimination from the body.

CERENIS is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Capitalizing on its expertise, Cerenis is developing the first HDL-based targeting drug delivery platform dedicated to the oncology field (immuno-oncology and chemotherapy).

CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.



### Contacts:

**Cerenis**  
Jean-Louis Dasseux  
CEO  
info@cerenis.com  
Tel: +33 (0)5 62 24 09 49

**NewCap**  
Investors relations  
Emmanuel Huynh / Louis-Victor Delouvrier  
cerenis@newcap.eu  
Tel: +33 (0)1 44 71 98 53